M2BPGi Correlated with Immunological Biomarkers and Further Stratified Recurrence Risk in Patients with Hepatocellular Carcinoma
I‐Cheng Lee(National Yang Ming Chiao Tung University), Yi‐Hsiang Huang(First Hospital of Lanzhou University)
Cited by 9
Related Papers
Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|Liver International|2016|225
2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations
|Journal of the Formosan Medical Association|2020|98
Taiwan consensus statement on the management of chronic hepatitis B
|Journal of the Formosan Medical Association|2018|86
2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population
|Journal of the Formosan Medical Association|2020|85